Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical trial of AVR-RD-03 in Pompe's disease

X
Trial Profile

A Phase 1/2 clinical trial of AVR-RD-03 in Pompe's disease

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVR RD 03 (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions
  • Sponsors AVROBIO; Tectonic Therapeutic
  • Most Recent Events

    • 20 Jun 2024 According to a Tectonic Therapeutic media release, AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic.
    • 17 Mar 2022 According to a AVROBIO media release, the company plan to engage with regulatory agencies on the clinical development strategy and plan to initiate this clinical trial in 2023, subject to regulatory clearance.
    • 04 Jan 2022 According to a AVROBIO media release, the company plans to initiate this trial in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top